GlassScriptPhysician profile
John T Oo
NPI 1396265864
$11,137.71
in general payments reported to CMS, 2019-2025
55 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,033 · 2022: $3,196 · 2023: $1,215 · 2024: $1,527 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878 · Education: $30.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.13 |
| Education | $30.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,822.34 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,006.60 | 2021-2024 | Xarelto |
| Amgen INC. | $858.92 | 2021-2023 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $853.27 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $683.76 | 2021-2025 | |
| Glaxosmithkline, LLC. | $670.27 | 2021-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $656.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.91 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $291.00 | 2021-2024 | Mounjaro, Zepbound, Reyvow |
| Ironwood Pharmaceuticals, INC | $263.95 | 2021-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $245.56 | 2022-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.39 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.23 | 2021-2023 | Jardiance |
| Medtronic, INC. | $197.08 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Merck Sharp & Dohme LLC | $190.62 | 2021-2023 | Steglatro, Belsomra |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.